How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update

Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about: • His dd-cfDNA “surveillance journey” and protocol development.

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protoc

How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use

In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her

Inside the ProActive Study- How Dr Sanjeev Akkina and Dr. Jessica Coleman approach the continuity of transplant recipient care

How Dr. Anand championed a surveillance protocol informed by his deep experience and research

How Dr. Batarse advocates for his patients upon early recognition of subtle rejection using cfDNA

How Dr. Athreya uses a Prospera™ surveillance protocol for his kidney-pancreas recipients

How Professor Viklicky used Prospera™ to monitor treatment response in both ABMR and TCMR cases

Fetal RhD NIPT: do all Rh negative patients need Rh immune globulin?

Leveraging Signatera Residual Disease Test (MRD) to Support More Patients Who Can Benefit from Hereditary Cancer Testing

New Hereditary Cancer Alert Program (HCAP) Pilot Increase Patients Tested by 200%

The evolution of NIPT: what comes next

In this talk, we will highlight how early, highly accurate prenatal screening optimizes outcomes for patients with 22q11.2 deletion syndrome, and review recently-published data from a large clinical v